Fascioliasis Market

1
Global Fascioliasis Market Is Estimated To
Witness High Growth Owing To Novartis AG and
Increasing Awareness
The global Fascioliasis Market is estimated to
be valued at US 361.3 million in 2023 and is
expected to exhibit a CAGR of 4.52 over the
forecast period 2023-2030, as highlighted in a
new report published by Coherent Market
Insights. Market Overview Fascioliasis is a
parasitic infection caused by Fasciola hepatica
and Fasciolopsis buski worms. This infection
affects the liver and bile ducts of mammals,
including humans. The market for fascioliasis
treatment is driven by the increasing prevalence
of the disease, particularly in developing
countries. The use of antiparasitic drugs, such
as triclabendazole and bithionol, is the primary
mode of treatment. The market also includes
diagnostic tests and support therapies for
managing the symptoms of the disease. Market
Dynamics The market for fascioliasis treatment
is driven by two key factors. First, the
increasing prevalence of the disease in certain
regions, especially in developing countries,
drives the demand for treatment options. For
example, in areas like South America, where
animal husbandry is common, there is a high risk
of contamination and transmission of the
parasites to humans. Second, the growing
awareness about the disease and its potential
impact on human health is leading to increased
diagnosis and treatment. Governments and
non-profit organizations are actively involved in
raising awareness and providing access to
treatment options in affected regions. For
instance, Novartis AG, a key player in the
market, has been actively involved in conducting
research and providing treatment options for
fascioliasis. Their commitment to the
development of new therapies and collaborations
with healthcare organizations is driving the
market growth. SWOT Analysis - Strength
Increasing awareness about fascioliasis and its
impact on human health - Weakness Limited
availability of specific treatment options -
Opportunity Unmet treatment needs in certain
regions and potential for market expansion -
Threat Limited healthcare infrastructure and
lack of access to treatment in rural areas Key
Takeaways - The global fascioliasis market is
expected to witness high growth, exhibiting a
CAGR of 4.52 over the forecast period, due to
increasing awareness and prevalence of the
disease. - The Asia Pacific region is expected
to dominate the market due to the high burden of
fascioliasis in countries like China and India,
coupled with increasing healthcare expenditure
and government initiatives. - Key players
operating in the global fascioliasis market are
Novartis AG, AMGIS Lifescience Ltd., Romark,
AbbVie Inc., Merck KGaA, AdvaCare Pharma, Intas
Pharmaceuticals Ltd., Procyon Life Sciences,
Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical
Industries Ltd., RV Lifesciences Limited, Grampus
Laboratories, and Janssen Pharmaceuticals, Inc.
Novartis AG is a prominent player in the market,
actively involved in research and development
activities to provide effective treatment
options.
2
In conclusion, the global fascioliasis market
is expected to witness significant growth due to
increasing awareness and prevalence of the
disease. The market is driven by key players like
Novartis AG, who are committed to developing
innovative treatment options. The market also
presents opportunities for expansion in regions
with unmet treatment needs. However, challenges
such as limited healthcare infrastructure and
access to treatment in rural areas need to be
addressed to ensure better management of
fascioliasis.